Your browser doesn't support javascript.
loading
An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.
Florek, Kelsey R; Campos, Luiza M; Braun, Katarina M; McLean, Huong Q; King, Jennifer P; Flannery, Brendan; Belongia, Edward A; Friedrich, Thomas C.
Afiliación
  • Florek KR; Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI 53706, USA.
  • Campos LM; Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI 53706, USA.
  • Braun KM; Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI 53706, USA.
  • McLean HQ; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield 54449, WI, USA.
  • King JP; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield 54449, WI, USA.
  • Flannery B; Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta 30333, GA, USA.
  • Belongia EA; Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 North Oak Ave, Marshfield 54449, WI, USA. Electronic address: belongia.edward@marshfieldclinic.org.
  • Friedrich TC; Department of Pathobiological Sciences, University of Wisconsin School of Veterinary Medicine, Madison, WI 53706, USA; Wisconsin National Primate Research Center, Madison, WI 53715, USA. Electronic address: thomasf@primate.wisc.edu.
Vaccine ; 36(5): 758-764, 2018 01 29.
Article en En | MEDLINE | ID: mdl-29249543
ABSTRACT

BACKGROUND:

Influenza vaccination may provide a "back-boost" to antibodies against previously encountered strains. If the back-boost effect is common, this could allow more aggressive vaccine updates, as emerging variants would be expected to both elicit de-novo responses and boost pre-existing responses against recently circulating strains. Here we used the emergence of an antigenically novel A(H3N2) strain to determine whether an antigenically updated vaccine boosted antibodies against historical strains.

METHODS:

We performed hemagglutination-inhibition (HI) assays on pre- and post-vaccination sera from 124 children 5-17 years old who received 2015-2016 inactivated influenza vaccine, containing an antigenically updated A(H3N2) strain. We evaluated the mean fold increase in HI titer against both the 2015-2016 vaccine strain and representative strains from two prior antigenic clusters. Factors associated with post-vaccination titers against historical strains were evaluated using linear regression, adjusting for baseline titer.

RESULTS:

Geometric mean titers against each antigen examined increased significantly after vaccination (P < .0001). Mean fold increase was 3.29 against the vaccine strain and 1.22-1.46 against historical strains. Response to vaccine strain was associated with increased post-vaccination titers against historical strains.

CONCLUSIONS:

A vaccine containing an antigenically novel A(H3N2) strain modestly boosted antibody responses against historical influenza strains in children.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Anticuerpos Antivirales / Antígenos Virales Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana / Subtipo H3N2 del Virus de la Influenza A / Anticuerpos Antivirales / Antígenos Virales Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos